Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
02257 SIRNAOMICS-B
53.600+0.900+1.71%
Market Close
02/09 16:08 CCT
High
54.750
Open
52.800
Turnover
4.24M
Low
52.350
Pre Close
52.700
Volume
78.75K
Price Forecast
News
Comment
Sirnaomics Unit to Present Research Data on Colon Cancer Vaccine at Conference
08:57 PM EST, 02/06/2023 (MT Newswires) -- Sirnaomics (HKG:2257) unit RNAimmune will present its mRNA cancer vaccine program at a cancer research conference in Orlando, Florida, a Tuesday filing said.
Sirnaomics to Fast-Track Development of Skin Cancer Treatment
05:48 AM EST, 02/01/2023 (MT Newswires) -- Sirnaomics (HKG:2257) will fast-track the development of its STP705 medication for the treatment of non-melanoma skin cancers, a Wednesday filing said. The c
Sirnaomics Shareholders to Vote on Grant of 1.5 Million Share Options to 119 Grantees
04:59 AM EST, 01/23/2023 (MT Newswires) -- Shareholders of Sirnaomics (HKG:2257) will meet on Feb. 3 to vote on the grant of around 1.5 million share options to 119 grantees for HK$58.9 apiece. Of thi
Sirnaomics Unit Subscribes to $5 Million Shares Issued by Cayman Islands Investment Fund
04:49 AM EST, 12/30/2022 (MT Newswires) -- Sirnaomics (HKG:2257) unit Sirnaomics (Hong Kong), on Thursday, subscribed to $5 million worth of Class B shares from TradArt Flagship Investment's segregate
Sirnaomics' Tumor Treatment Shows Efficacy, Safety in Phase 1 Clinical Trial
10:42 PM EST, 12/20/2022 (MT Newswires) -- Sirnaomics' (HKG:2257) STP707 tumor treatment showed efficacy and safety during its phase 1 clinical trial, according to a Tuesday stock filing. The antitumo
Sirnaomics' Anti-Skin Cancer Drug Trial Shows Positive Results in 78% of Patients
07:40 AM EST, 12/14/2022 (MT Newswires) -- Sirnaomics (HKG:2257) said 78% of its patients in the second phase of its STP705 clinical trial showed positive responses to the drug, the biopharmaceutical
Sirnaomics Names CFO
07:10 PM EST, 11/15/2022 (MT Newswires) -- Sirnaomics (HKG:2257) appointed Yip Wing Kei as chief financial officer, effective Nov. 15, according to a same-day disclosure. Yip was re-designated from CF
Sirnaomics Forecasts 2025 US Launch of Skin Cancer Treatment
05:29 AM EST, 11/08/2022 (MT Newswires) -- Sirnaomics (HKG:2257) expects its core product STP705 to reach phase 3 clinical trial for the treatment of squamous cell carcinoma in situ, a form of skin ca
Sirnaomics Doses First Patient for Phase I Clinical Trial of Drug for Abdominoplasty
07:46 PM EST, 11/07/2022 (MT Newswires) -- Sirnaomics (HKG:2257) dosed the first patient in its Phase I clinical trial of STP705 for adults undergoing abdominoplasty for medical aesthetics treatment,
San Nuo Pharmaceuticals-BRV 2022 interim report
Company Overview
More
sirNomics is the first and only clinical-stage RNA therapy biopharmaceutical company with significant market positions in both China and the US. Through exploration and development of innovative drugs, they are used in human diseases with significant unmet medical needs. The clinical development pipeline focuses on oncology and fibrosis indications.
Our management team shares extensive experience and ability to explore, develop, and commercialize RNAi therapies.
Our mission is to be a fully integrated international biopharmaceutical company that relies on our deep experience in RNA therapy and novel delivery platform technology to rapidly discover, develop and (if approved) commercialize a range of transformative therapies and vaccines for patients suffering from a variety of rare and marketable diseases.
CEO： Yang Lu
Market： Hong Kong motherboard
Listing Date： 12/30/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet